ArticleCurrent issues in molecular biology2026
Radiosensitive HSPC Subsets Define Early Hematopoietic Injury and Enable H-ARS Therapeutic Screening.
Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Early hematopoietic injury is a critical determinant of hematopoietic acute radiation syndrome (H-ARS), yet biologically relevant cellular endpoints and optimal evaluation windows for therapeutic screening remain poorly defined. Here, we combined high-dimensional mass cytometry (CyTOF) and flow cytometry to characterize early hematopoietic stem and progenitor cell (HSPC) remodeling following 6.5 Gy total-body irradiation. Radiation exposure induced rapid bone marrow injury, with substantial cellular loss and reduced viability occurring within hours after irradiation. CyTOF analysis revealed that radiation-induced injury was characterized by selective remodeling rather than uniform depletion of the HSPC compartment. While long-term hematopoietic stem cells (LT-HSCs) were relatively preserved, short-term HSCs (ST-HSCs), multipotent progenitors (MPPs), and megakaryocyte-erythroid progenitors (MEPs) exhibited marked reductions during the early phase after irradiation. Importantly, surviving cells retained partial differentiation capacity during this period, indicating that the early post-irradiation phase represents a biologically informative window for therapeutic evaluation. These radiosensitive populations were subsequently validated using a simplified flow cytometry platform and remained detectable under short-term in vitro culture conditions. Collectively, our findings identify key radiosensitive HSPC subsets and establish an early hematopoietic injury framework that integrates optimal evaluation timing with practical cellular endpoints for H-ARS therapeutic screening and radiomitigator development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.